The WID-CIN test identifies women with, and at risk of, cervical intraepithelial neoplasia grade 3 and invasive cervical cancer

Table 3 Specificity (CIN1 or normal cytology) and sensitivity (detection of CIN3 or invasive cancer) of specific strategies to triage hrHPV-positive women (95% confidence intervals)

	Specificity ≤ CIN1 (95% CI)	Sensitivity CIN3+ (95% CI)
Cytology (PAP) [5]	76.1% (74.6–77.7)	51.9% (45.4–58.3)
Dual stain cytology (p16/Ki-67) [5]	75.6% (74.0–77.1)	74.9% (69.0–80.2)
QIAsure™ methylation test [17]	78.3% (76.4–80.0)	78.6% (73.5–83.7)
Methylation markers (pooled meta-analysis)	75.9% (71.9–79.5)	70.5% (64.8–75.6)
WID-CIN test	78.0% (73.1–82.9)	89.7% (83.3–96.1)

The WID-CIN index has been fixed at 78% (based on the highest level by the other strategies) in order to make the sensitivity comparable. Wright et al. [5] included all women ≥25 years of age with valid cervical biopsy and cobas®HPV test results from the cross-sectional phase of the ATHENA study who were referred for colposcopy. Bonde et al. [17] conducted an EU-multicenter, retrospective study (samples collected at four European centers) to evaluate the clinical performance of the FAM19A4/miR124-2 methylation-based molecular triage test as a substitute or addition to cytology as reflex testing of HPV screen-positive women. Would we have excluded women < 29 years of age, the sensitivity of the WID-CIN test at a fixed specificity of 78% is 92.2%

ISSN: 1756-994X